Longitudinal evaluation of SNOT-22 can distinguish patients with chronic rhinosinusitis with nasal polyps who respond quickly ...

Guidance for ARIKAYCE remains unchanged at $405 million to $425 million for full-year 2025. The company reiterated its focus on achieving a smooth launch for brensocatib in the U.S. and expanding its ...

Topical deep delivery of corticosteroids into the sinonasal cavity improves symptoms and sleep in patients with chronic rhinosinusitis.

It's the first time that Chinese scholars have published a guideline-type document in a top-tier international journal in ...

For patients with chronic sinusitis and nasal polyps, nasal endoscopic surgery can remove polyps in a shorter time, with less ...

Chronic rhinosinusitis with nasal polyps (CRSwNP) inflammatory endotypes are associated with long-term air pollutant and allergen exposure.

Research and development expenses were $25.8 million for the quarter ended March 31, 2025, compared to $11.7 million for the ...